Literature DB >> 8119049

Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial.

N Holford1, P Black, R Couch, J Kennedy, R Briant.   

Abstract

The optimal serum concentration of theophylline for the management of acute airways obstruction was evaluated by comparing the response to target concentrations at the extremes of the usual therapeutic range. 174 patients requiring intravenous theophylline were randomly assigned to a target concentration of 10 or 20 mg/L. Control of theophylline dosage using measured theophylline concentrations and evaluation of efficacy and toxicity was performed under double-blind conditions. 87 patients (50%) required hospital admission. Of these, 54 patients (62%) were followed throughout their hospital admission and reviewed at an outpatient clinic approximately 1 week after discharge. The duration of hospital stay, and rate and extent of improvement in peak expiratory flow rate were not different between the groups. There was significantly more toxicity in the 20 mg/L group. The initial target concentration for theophylline in the management of acute airway obstruction should be 10 mg/L under circumstances where concentration is used to control theophylline dosages.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8119049     DOI: 10.2165/00003088-199325060-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  16 in total

1.  A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.

Authors:  D Murciano; M H Auclair; R Pariente; M Aubier
Journal:  N Engl J Med       Date:  1989-06-08       Impact factor: 91.245

2.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

3.  Theophylline--how much is enough?

Authors:  R D Fairshter; W W Busse
Journal:  J Allergy Clin Immunol       Date:  1986-04       Impact factor: 10.793

4.  Method for the rapid estimation of the total body drug clearance and adjustment of dosage regimens in patients during a constant-rate intravenous infusion.

Authors:  W L Chiou; M A Gadalla; G W Peng
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma.

Authors:  D Siegel; D Sheppard; A Gelb; P F Weinberg
Journal:  Am Rev Respir Dis       Date:  1985-08

7.  Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline.

Authors:  S Vozeh; G Kewitz; A Perruchoud; M Tschan; C Kopp; M Heitz; F Follath
Journal:  Am Rev Respir Dis       Date:  1982-02

8.  A controlled trial of methylprednisolone in the emergency treatment of acute asthma.

Authors:  B Littenberg; E H Gluck
Journal:  N Engl J Med       Date:  1986-01-16       Impact factor: 91.245

9.  Aminophylline therapy for acute bronchospastic disease in the emergency room.

Authors:  K Wrenn; C M Slovis; F Murphy; R S Greenberg
Journal:  Ann Intern Med       Date:  1991-08-15       Impact factor: 25.391

10.  Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators.

Authors:  J Coleridge; P Cameron; J Epstein; H Teichtahl
Journal:  Aust N Z J Med       Date:  1993-08
View more
  24 in total

1.  Target concentration intervention: beyond Y2K.

Authors:  N H Holford
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner; M G Matera
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 3.  Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?

Authors:  A Grahnén; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Randomized exposure-controlled trials; impact of randomization and analysis strategies.

Authors:  Kristin E Karlsson; Anders Grahnén; Mats O Karlsson; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

Review 5.  Clinical pharmacology = disease progression + drug action.

Authors:  Nick Holford
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 6.  Community-based therapeutic drug monitoring. Useful development or unnecessary distraction?

Authors:  M Campbell
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 7.  Target concentration strategy for cyclosporin monitoring.

Authors:  R G Morris
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

8.  Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.

Authors:  B Royer; W Yin; M Pegram; N Ibrahim; C Villanueva; D Mir; F Erlandsson; X Pivot
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

9.  Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.

Authors:  Bernard Royer; Vincent Jullien; Emmanuel Guardiola; Bruno Heyd; Bruno Chauffert; Jean-Pierre Kantelip; Xavier Pivot
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials.

Authors:  R Graham Barr; Brian H Rowe; Carlos A Camargo
Journal:  BMJ       Date:  2003-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.